Cell Bank Characterization and Adventitious Agent Testing Inspection
Inspect master and working cell bank characterization records for identity, purity, sterility, mycoplasma, and adventitious agent testing before release. Use it to catch missing traceability, invalid assays, and unresolved deviations early.
Trusted by frontline teams 15 years of frontline software AI customization in seconds
Built for: Biopharmaceutical Manufacturing · Cell And Gene Therapy · Contract Testing Laboratories · Vaccine Development
Overview
This inspection template is for reviewing the documented characterization package for a master cell bank or working cell bank before the bank is released, transferred, or used in manufacturing. It walks the reviewer through bank identification, identity and purity evidence, sterility and mycoplasma testing, adventitious agent and viral safety results, and the final quality disposition. The goal is to confirm that the bank being reviewed matches the approved records, that the required assays were performed with approved methods, and that any discrepancy, invalid result, or atypical finding has a documented investigation and outcome.
Use this template when a cell bank package needs formal QA review, when a new testing report set arrives from an internal or contract lab, or when a deviation has to be closed before release. It is especially useful for programs that rely on a chain of custody from bank vial to test lab and need a clear record of who reviewed what and when. Do not use it as a substitute for the actual laboratory methods, and do not use it for routine environmental monitoring or general equipment checks. If the bank type, assay panel, or acceptance criteria are not defined in an approved protocol or SOP, stop and resolve that gap first. The template is designed to surface missing traceability, mismatched identifiers, incomplete controls, and release decisions made before the full characterization package is complete.
Standards & compliance context
- This template supports GMP-style quality review expectations commonly applied to biologics and cell-based products, where identity, purity, and contamination control must be documented before release.
- The structure aligns with FDA and EMA quality system expectations for traceable records, approved methods, deviation handling, and documented disposition of non-conformances.
- The adventitious agent section helps demonstrate control of viral safety risks using methods and panels appropriate to the cell bank type and intended use.
- Sterility and mycoplasma checks support microbiological control expectations commonly reflected in pharmacopeial and industry guidance for biological materials.
- If your program uses contract testing, the template helps confirm that the external lab package still meets your internal quality and release requirements.
General regulatory context for orientation only — verify current requirements with counsel or the relevant agency before relying on this template for compliance.
What's inside this template
Inspection Scope and Cell Bank Identification
This section matters because it ties the review to the exact bank, lot, passage, and approved protocol so the rest of the inspection is anchored to the right material.
- Cell bank type identified as MCB or WCB
- Bank lot, passage, and container identifiers match approved records
- Inspection scope references the approved characterization protocol or SOP
- Chain of custody and sample traceability are documented from bank to test lab
- Inspection date and reviewer are recorded
Identity and Purity Characterization
This section matters because it confirms the bank is the intended cell line and has not shown evidence of cross-contamination, drift, or mixed population.
- Identity test method is defined and approved
- Identity result confirms the bank matches the reference cell line
- Purity assessment performed for cross-contamination or mixed population
- Morphology, growth characteristics, or marker profile are consistent with the intended cell line
- Any identity or purity discrepancy has documented investigation and disposition
Sterility and Mycoplasma Testing
This section matters because microbial contamination can invalidate the bank and must be clearly negative or otherwise dispositioned before release.
- Sterility test was performed on the required bank sample set
- Sterility result is negative / within acceptance criteria
- Mycoplasma test was performed using an approved method
- Mycoplasma result is negative / within acceptance criteria
- Any out-of-specification or invalid sterility/mycoplasma result has documented retest or deviation handling
Adventitious Agent and Viral Safety Panel
This section matters because it verifies that the required safety assays were performed with acceptable controls and no detected contamination or unresolved signal.
- Testing panel includes the required adventitious agent assays for the cell bank type
- Viral screening or detection methods are approved and fit for intended use
- Results show no detected adventitious agent contamination
- Positive and negative controls met acceptance criteria
- Any detected signal, inconclusive result, or assay failure has documented investigation and disposition
Review, Deviations, and Release Decision
This section matters because a complete package still needs a documented quality decision, impact assessment, and assigned follow-up actions for any deficiency.
- All required test reports are present, legible, and signed or approved
- Deviations, OOS, or atypical findings are documented with impact assessment
- Final release, rejection, or restricted-use decision is documented
- Quality unit or authorized reviewer approval is recorded
- Follow-up actions and due dates are assigned for any deficiency
How to use this template
- 1. Enter the bank type, lot, passage, container identifiers, inspection date, and the approved protocol or SOP so the review is tied to the exact characterization package.
- 2. Verify that the chain of custody and sample traceability connect the bank material to the test laboratory and that all report identifiers match the approved records.
- 3. Review identity and purity evidence first, confirming the method was approved, the result matches the reference cell line, and any discrepancy has an investigation and disposition.
- 4. Check sterility, mycoplasma, and adventitious agent results against the required acceptance criteria, including control performance and any retest or invalid-result handling.
- 5. Confirm that all reports are legible, signed or approved, deviations are assessed for impact, and the final release, rejection, or restricted-use decision is documented with follow-up actions.
Best practices
- Review the bank identifiers against the source records before reading any test result so a mismatched vial or passage level is caught early.
- Treat identity and purity as separate checks, because a cell line can match the reference profile while still showing evidence of mixed population or cross-contamination.
- Flag any sterility, mycoplasma, or viral safety result that is invalid, inconclusive, or out of specification until the retest path or deviation is closed.
- Confirm that positive and negative controls met acceptance criteria before accepting a negative assay result.
- Photograph or attach the exact report pages, chromatograms, or assay summaries that support the review so the release record is self-contained.
- Escalate any missing chain-of-custody link between the bank and the test lab, because traceability gaps can undermine the entire characterization package.
- Do not accept a release decision if the quality unit approval is missing or if follow-up actions have no owner and due date.
What this template typically catches
Issues teams running this template most often surface in practice:
Common use cases
Frequently asked questions
What does this cell bank characterization inspection template cover?
It covers the record review needed to confirm a master cell bank or working cell bank was characterized as intended before use or release. The template checks identity, purity, sterility, mycoplasma, adventitious agent testing, chain of custody, and final disposition. It is designed for QA, QC, and manufacturing review of the documented evidence, not for running the lab assays themselves.
When should this inspection be used?
Use it when a new MCB or WCB is created, qualified, transferred, or released for manufacturing. It is also useful after a deviation, assay failure, retest, or change to the testing panel or contract lab. If the bank is already in routine use, this template still helps verify that the release package is complete and defensible.
Who should complete the inspection?
A quality reviewer, QC lead, or other authorized reviewer should complete it, with input from the cell culture, virology, or microbiology functions as needed. The person reviewing should be able to judge whether the methods are approved, the results meet acceptance criteria, and any discrepancy has been investigated. Final release decisions should remain with the designated quality authority.
How often should cell bank characterization be reviewed?
Review it each time a bank lot is created, requalified, or transferred to a new testing program or facility. For ongoing programs, use it whenever a new characterization package is issued or when a change affects the bank's risk profile, such as a new assay, new lab, or new source material. It is not a substitute for routine in-process monitoring of cell culture operations.
How does this template align with regulatory expectations?
It supports the documentation discipline expected under GMP-style quality systems and biologics control programs. The structure aligns with common expectations from FDA, EMA, and ICH-based quality practices for identity, purity, sterility, mycoplasma, and adventitious agent control. It also helps demonstrate that deviations, invalid results, and release decisions were handled through a formal quality process.
What are the most common mistakes this inspection catches?
Common misses include incomplete chain-of-custody records, mismatched bank identifiers, missing approval of the identity method, and sterility or mycoplasma results that were not clearly tied to the correct sample set. It also catches weak documentation around inconclusive viral safety results, missing control acceptance, and release decisions made before all reports were signed. These are the kinds of gaps that can delay batch release or trigger a quality investigation.
Can this template be customized for different cell types or testing panels?
Yes. You can tailor the inspection to the specific bank type, such as mammalian, insect, or hybridoma cells, and to the required adventitious agent panel for that program. You can also add organization-specific acceptance criteria, lab vendors, sample identifiers, and escalation paths. The core walk-through should stay the same so reviewers do not miss traceability or disposition checks.
How does this differ from an ad hoc document review?
An ad hoc review often checks only whether reports exist, while this template forces a structured pass through identity, purity, sterility, mycoplasma, viral safety, and final release. That reduces the chance of overlooking an invalid assay, a missing control, or an unresolved discrepancy. It also creates a repeatable audit trail that is easier to defend during internal or external inspection.
What should I integrate this with?
It pairs well with your document control system, deviation/CAPA workflow, LIMS, and batch release records. If your organization tracks sample genealogy or chain of custody in a separate system, link those records in the inspection. That makes it easier to verify that the bank lot reviewed here matches the lab reports and the approved protocol.
Related templates
Go deeper on the topic
-
A daily huddle is a brief (10–15 minute) standing meeting held at the start of a shift or workday to align the team on priorities, surface issues, and...
-
A deskless worker is any employee whose job happens without a desk, a company laptop, or a fixed workstation. They're roughly 80% of the global workforce —...
-
A frontline employee app is a phone-first application that gives hourly, field, and deskless workers access to their schedule, pay, announcements, training,...
-
A frontline worker is any employee whose job happens away from a desk — on a production floor, in a patient room, behind a store counter, in a customer's...
-
Discover 4 proven keys to successful project management and team collaboration — from transparent goal-setting to real-time communication and workflow...
-
Boost team collaboration with modern tools that improve visibility, accountability, and communication for stronger project outcomes.
-
Compare the best employee apps of 2026—MangoApps, Blink, WorkJam, Flip, and more—to find the right fit for your frontline workforce.
-
Discover why an employee text alert system is essential for frontline safety, faster emergency response, and two-way communication across your entire workforce.
Ready to use this template?
Get started with MangoApps and use Cell Bank Characterization and Adventitious Agent Testing Inspection with your team — pricing built for small business.
